IS6377A - Pýrrólidínasetamíð afleiður einar sér eða í samsetningu til meðhöndlunar á truflunum í miðtaugakerfi - Google Patents

Pýrrólidínasetamíð afleiður einar sér eða í samsetningu til meðhöndlunar á truflunum í miðtaugakerfi

Info

Publication number: IS6377A
Authority: IS; Iceland
Prior art keywords: treatment; combination; nervous system; central nervous; system disorders
Prior art date: 1999-12-01

Application number

IS6377A

Other languages

English (en)

Inventor

Lamberty Yves

Matagne Alain

Klitgaard Henrik

Waegemans Tony

Original Assignee

Ucb, S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-01

Filing date

2002-05-10

Publication date

2002-05-10

2002-05-10 Application filed by Ucb, S.A. filed Critical Ucb, S.A.

2002-05-10 Publication of IS6377A publication Critical patent/IS6377A/is

Links

JZQKDDCNNQFGRM-UHFFFAOYSA-N acetamide;pyrrolidine Chemical class CC(N)=O.C1CCNC1 JZQKDDCNNQFGRM-UHFFFAOYSA-N 0.000 title 1
208000015114 central nervous system disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)

IS6377A 1999-12-01 2002-05-10 Pýrrólidínasetamíð afleiður einar sér eða í samsetningu til meðhöndlunar á truflunum í miðtaugakerfi IS6377A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP99124269		1999-12-01
EP99123803		1999-12-01
PCT/EP2000/011808 WO2001039779A1 (en)	1999-12-01	2000-11-27	A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders

Publications (1)

Publication Number	Publication Date
IS6377A true IS6377A (is)	2002-05-10

Family

ID=26153183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6377A IS6377A (is)	1999-12-01	2002-05-10	Pýrrólidínasetamíð afleiður einar sér eða í samsetningu til meðhöndlunar á truflunum í miðtaugakerfi

Country Status (32)

Country	Link
US (2)	US6903130B1 (is)
EP (4)	EP1600167A3 (is)
JP (2)	JP4249415B2 (is)
KR (1)	KR20030016205A (is)
CN (1)	CN100525761C (is)
AR (1)	AR026610A1 (is)
AT (1)	ATE361751T1 (is)
AU (1)	AU773418B2 (is)
BG (1)	BG106708A (is)
BR (1)	BR0015974A (is)
CA (2)	CA2392879C (is)
CO (1)	CO5261590A1 (is)
CZ (1)	CZ20021904A3 (is)
DE (1)	DE60034815T2 (is)
EE (1)	EE200200274A (is)
ES (1)	ES2287039T3 (is)
HK (1)	HK1052647B (is)
HU (1)	HUP0204023A3 (is)
IL (2)	IL149530A0 (is)
IS (1)	IS6377A (is)
MX (1)	MXPA02005275A (is)
MY (1)	MY127980A (is)
NO (1)	NO20022585L (is)
NZ (1)	NZ518901A (is)
PL (1)	PL357472A1 (is)
RO (1)	RO121085B1 (is)
RU (1)	RU2261093C2 (is)
SA (1)	SA01210655B1 (is)
SK (1)	SK7492002A3 (is)
TW (1)	TWI238062B (is)
WO (1)	WO2001039779A1 (is)
YU (1)	YU37602A (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0004297D0 (en)	2000-02-23	2000-04-12	Ucb Sa	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US7683071B2 (en)	2000-07-26	2010-03-23	Taro Pharmaceuticals Industries Ltd.	Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en)	2001-07-26	2004-06-29	Taro Pharmaceutical Industries Ltd.	Non-sedating barbiturate compounds as neuroprotective agents
WO2002053153A1 (en) *	2000-12-28	2002-07-11	Daiichi Pharmaceutical Co., Ltd.	Medicines for treatment and prevention of neurogenic pain
WO2002067931A1 (en) *	2001-02-23	2002-09-06	Johns Hopkins University	Treatment of tics, tremors and related disorders
JP2004535433A (ja) *	2001-06-20	2004-11-25	メルク　エンド　カムパニー　インコーポレーテッド	糖尿病治療用のジペプチジルペプチダーゼ阻害薬
US7544681B2 (en)	2001-09-27	2009-06-09	Ramot At Tel Aviv University Ltd.	Conjugated psychotropic drugs and uses thereof
CA2461961A1 (en) *	2001-10-08	2003-04-17	Ucb, S.A.	Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
AU2003242538A1 (en) *	2002-05-14	2003-11-11	Ucb, S.A.	Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
JP2006516390A (ja)	2002-12-03	2006-07-06	ユセベソシエテアノニム	発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法
DE60324703D1 (de) *	2002-12-11	2008-12-24	Taro Pharma Ind	Barbitursäure derivaten.
WO2004083180A1 (en) *	2003-03-18	2004-09-30	Hetero Drugs Limited	Novel crystalline forms of levetiracetam
GB0307860D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Organic compounds
US20070037882A1 (en) *	2003-04-22	2007-02-15	Astellas Pharma Inc.	Remedy for cerebral neurodegenerative diseases using ppar agonist
US8569058B2 (en)	2003-10-03	2013-10-29	Ono Pharmaceutical Co., Ltd.	Nerve regeneration promoters
JP2008534522A (ja)	2005-03-30	2008-08-28	ジェンファームインク	医薬組成物のための複合ステップ製造方法
US20060252745A1 (en)	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2006127300A1 (en) *	2005-05-24	2006-11-30	Cambrex Charles City, Inc.	SYNTHESIS OF (S)-α-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE
US8802142B2 (en)	2005-07-26	2014-08-12	Ucb Pharma, S.A.	Pharmaceutical compositions comprising levetiracetam and process for their preparation
US20070043120A1 (en) *	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
EP1754476A1 (en) *	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
FR2890563B1 (fr) *	2005-09-09	2007-10-19	Servier Lab	Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
ES2317452T3 (es) *	2006-01-24	2009-04-16	Teva Pharmaceutical Industries Limited	Formulaciones de levetiracetam y procedimientos para su preparacion.
ES2531118T5 (es)	2006-06-15	2022-06-14	Ucb Pharma Gmbh	Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
CN101511388B (zh) *	2006-07-17	2012-10-24	特拉维夫大学拉莫特有限公司	含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
WO2008095221A1 (en)	2007-02-07	2008-08-14	Gosforth Centre (Holdings) Pty Ltd	Treatment of adhd
ITMI20070770A1 (it) *	2007-04-16	2008-10-17	Brane Discovery S R L	Impiego di dimiracetam nel trattamento del dolore cronico
AU2012201853B2 (en) *	2007-04-16	2013-06-27	Neurotune Ag	Use of dimiracetam in the treatment of chronic pain
WO2009101616A1 (en)	2008-02-11	2009-08-20	Ramot At Tel Aviv University Ltd.	Novel conjugates for treating neurodegenerative diseases and disorders
JP2011529923A (ja) *	2008-08-06	2011-12-15	ゴスフォースセンター（ホールディングス）プロプライエタリーリミテッド	精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
DK2346500T3 (en)	2008-10-16	2017-07-17	Univ Johns Hopkins	Methods and compositions for improving cognitive function
PL389364A1 (pl)	2009-10-23	2011-04-26	Uniwersytet Jagielloński	Nowe zastosowanie pochodnych 2-pirolidonu
EP2539857A4 (en)	2010-02-24	2013-07-24	Univ Ramot	CRYSTALLINE FORMS OF TRI MESYLATE SALT OF PERPHENAZINE GABA AND METHOD OF MANUFACTURING THEREOF
US8822539B2 (en) *	2010-03-28	2014-09-02	Children's Medical Center Corporation	Combination therapies: inhibitors of GABA transaminase and NKCC1
US8916610B2 (en)	2010-09-22	2014-12-23	Ramot At Tel-Aviv University Ltd.	Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
AU2018208662B2 (en) *	2012-11-14	2020-07-23	The Johns Hopkins University	Methods and Compositions for Treating Schizophrenia
JP6440625B2 (ja) *	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
EP2968220B1 (en)	2013-03-15	2021-05-05	Agenebio, Inc.	Methods and compositions for improving cognitive function
EP2968237A4 (en)	2013-03-15	2016-08-31	Univ Johns Hopkins	METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
KR101690175B1 (ko) *	2013-07-02	2016-12-27	경희대학교 산학협력단	고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물
RU2538724C1 (ru) *	2013-12-19	2015-01-10	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	Способ лечения эпилепсии
US10537573B2 (en) *	2014-01-21	2020-01-21	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL279202B2 (en)	2014-01-21	2023-09-01	Janssen Pharmaceutica Nv	Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
RU2563124C1 (ru) *	2014-04-28	2015-09-20	Федеральное государственное бюджетное учреждение "Федеральный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского" Министерства здравоохранения Российской Федерации (ФГБУ "ФМИЦПН им. В.П. Сербского" Минздрава России)	Способ диагностики шизофрении
MX384391B (es)	2015-05-22	2025-03-14	Agenebio Inc	Composiciones farmacéuticas de levetiracetam de liberación extendida.
JP2019531351A (ja) *	2016-10-14	2019-10-31	シーエヌエスバイオサイエンシーズ，インコーポレイティド	脊髄損傷者における神経障害性疼痛の治療
PL244071B1 (pl) *	2019-01-07	2023-11-27	Univ Jagiellonski	Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8412357D0 (en)	1984-05-15	1984-06-20	Ucb Sa	Pharmaceutical composition
GB8827389D0 (en)	1988-11-23	1988-12-29	Ucb Sa	Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP0408782A1 (en)	1989-07-18	1991-01-23	Nauchnoissledovatelski Chimikopharmatzevtichen Institut	Antihypoxic agent
GB9319732D0 (en)	1993-09-24	1993-11-10	Ucb Sa	Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5998380A (en) *	1995-10-13	1999-12-07	New England Medical Center Hospitals, Inc.	Treatment of migraine
WO1999031075A1 (en) *	1997-12-16	1999-06-24	Warner-Lambert Company	1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP1047414A1 (en)	1998-01-23	2000-11-02	Warner-Lambert Company	Gabapentin and its derivatives for the treatment of muscular and skeletal pain
DE19820381B4 (de) *	1998-05-07	2007-01-25	Trw Fahrwerksysteme Gmbh & Co Kg	Verfahren zur Beeinflussung der Ventilkennlinie
US6495601B1 (en)	1998-12-23	2002-12-17	Cytoscan Sciences Llc	Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
AU2384500A (en) *	1998-12-23	2000-07-12	Cytoscan Sciences L.L.C.	Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
DE60035232T2 (de) *	1999-07-01	2008-02-14	Pharmacia & Upjohn Co. Llc, Kalamazoo	(S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
AU2003225813A1 (en) *	2002-03-18	2003-10-08	Roger K. Cady	Preemptive prophylaxis of migraine
US20040116506A1 (en) *	2002-06-20	2004-06-17	Krusz John Claude	Use of levetiracetam for treating or preventing acute headaches
JP2006516390A (ja) *	2002-12-03	2006-07-06	ユセベソシエテアノニム	発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法

2000
- 2000-11-27 BR BR0015974-3A patent/BR0015974A/pt not_active Application Discontinuation
- 2000-11-27 EP EP05019209A patent/EP1600167A3/en not_active Withdrawn
- 2000-11-27 RO ROA200200730A patent/RO121085B1/ro unknown
- 2000-11-27 AT AT00977580T patent/ATE361751T1/de not_active IP Right Cessation
- 2000-11-27 YU YU37602A patent/YU37602A/sh unknown
- 2000-11-27 RU RU2002117279/15A patent/RU2261093C2/ru not_active IP Right Cessation
- 2000-11-27 CZ CZ20021904A patent/CZ20021904A3/cs unknown
- 2000-11-27 JP JP2001541511A patent/JP4249415B2/ja not_active Expired - Fee Related
- 2000-11-27 EP EP00977580A patent/EP1244456B1/en not_active Expired - Lifetime
- 2000-11-27 TW TW089125114A patent/TWI238062B/zh not_active IP Right Cessation
- 2000-11-27 MX MXPA02005275A patent/MXPA02005275A/es active IP Right Grant
- 2000-11-27 DE DE60034815T patent/DE60034815T2/de not_active Expired - Lifetime
- 2000-11-27 EP EP05019211A patent/EP1600168A3/en not_active Withdrawn
- 2000-11-27 EE EEP200200274A patent/EE200200274A/xx unknown
- 2000-11-27 AR ARP000106224A patent/AR026610A1/es unknown
- 2000-11-27 PL PL00357472A patent/PL357472A1/xx unknown
- 2000-11-27 KR KR1020027006987A patent/KR20030016205A/ko not_active Ceased
- 2000-11-27 WO PCT/EP2000/011808 patent/WO2001039779A1/en not_active Ceased
- 2000-11-27 NZ NZ518901A patent/NZ518901A/en unknown
- 2000-11-27 EP EP05019212A patent/EP1600169A3/en not_active Withdrawn
- 2000-11-27 CA CA002392879A patent/CA2392879C/en not_active Expired - Fee Related
- 2000-11-27 AU AU15241/01A patent/AU773418B2/en not_active Ceased
- 2000-11-27 CA CA002475026A patent/CA2475026A1/en not_active Abandoned
- 2000-11-27 CN CNB008165378A patent/CN100525761C/zh not_active Expired - Fee Related
- 2000-11-27 HU HU0204023A patent/HUP0204023A3/hu unknown
- 2000-11-27 IL IL14953000A patent/IL149530A0/xx active IP Right Grant
- 2000-11-27 US US10/148,347 patent/US6903130B1/en not_active Expired - Fee Related
- 2000-11-27 HK HK03104923.1A patent/HK1052647B/zh not_active IP Right Cessation
- 2000-11-27 SK SK749-2002A patent/SK7492002A3/sk unknown
- 2000-11-27 ES ES00977580T patent/ES2287039T3/es not_active Expired - Lifetime
- 2000-11-30 CO CO00091771A patent/CO5261590A1/es not_active Application Discontinuation
- 2000-12-01 MY MYPI20005634A patent/MY127980A/en unknown
2001
- 2001-01-20 SA SA01210655A patent/SA01210655B1/ar unknown
2002
- 2002-05-08 IL IL149530A patent/IL149530A/en not_active IP Right Cessation
- 2002-05-10 IS IS6377A patent/IS6377A/is unknown
- 2002-05-16 BG BG106708A patent/BG106708A/bg unknown
- 2002-05-31 NO NO20022585A patent/NO20022585L/no not_active Application Discontinuation
2005
- 2005-04-21 US US11/111,636 patent/US20050187205A1/en not_active Abandoned
2007
- 2007-11-14 JP JP2007295865A patent/JP2008056697A/ja active Pending

Also Published As

Publication number	Publication date
CZ20021904A3 (cs)	2002-11-13
DE60034815T2 (de)	2008-01-31
MXPA02005275A (es)	2003-02-17
CO5261590A1 (es)	2003-03-31
RO121085B1 (ro)	2006-12-29
ATE361751T1 (de)	2007-06-15
CA2392879A1 (en)	2001-06-07
US6903130B1 (en)	2005-06-07
WO2001039779A1 (en)	2001-06-07
IL149530A0 (en)	2002-11-10
EP1244456B1 (en)	2007-05-09
EE200200274A (et)	2003-06-16
EP1244456A1 (en)	2002-10-02
EP1600169A2 (en)	2005-11-30
BG106708A (bg)	2003-02-28
KR20030016205A (ko)	2003-02-26
NO20022585L (no)	2002-07-25
AR026610A1 (es)	2003-02-19
EP1600168A2 (en)	2005-11-30
AU773418B2 (en)	2004-05-27
JP2003515564A (ja)	2003-05-07
IL149530A (en)	2007-07-04
HUP0204023A3 (en)	2005-03-29
MY127980A (en)	2007-01-31
AU1524101A (en)	2001-06-12
EP1600167A2 (en)	2005-11-30
ES2287039T3 (es)	2007-12-16
PL357472A1 (en)	2004-07-26
SA01210655B1 (ar)	2006-10-29
CA2475026A1 (en)	2001-06-07
JP2008056697A (ja)	2008-03-13
RU2002117279A (ru)	2004-02-27
RU2261093C2 (ru)	2005-09-27
DE60034815D1 (de)	2007-06-21
CA2392879C (en)	2005-03-29
EP1600167A3 (en)	2009-09-30
TWI238062B (en)	2005-08-21
BR0015974A (pt)	2002-07-23
YU37602A (sh)	2005-07-19
HUP0204023A2 (hu)	2003-03-28
EP1600169A3 (en)	2009-09-23
NZ518901A (en)	2004-08-27
CN1402637A (zh)	2003-03-12
JP4249415B2 (ja)	2009-04-02
HK1052647B (zh)	2010-05-20
EP1600168A3 (en)	2009-09-23
SK7492002A3 (en)	2003-02-04
HK1052647A1 (zh)	2003-09-26
US20050187205A1 (en)	2005-08-25
CN100525761C (zh)	2009-08-12
NO20022585D0 (no)	2002-05-31

Publication	Publication Date	Title
IS6377A (is)	2002-05-10	Pýrrólidínasetamíð afleiður einar sér eða í samsetningu til meðhöndlunar á truflunum í miðtaugakerfi
IS6003A (is)	2001-07-13	Mónóamín endurupptökulatar til meðhöndlunar á truflunum í miðtaugakerfi
IL155589A0 (en)	2003-11-23	Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
PT2266594E (pt)	2015-08-05	Vegf para utilização no tratamento de distúrbios do sistema nervoso central
IS6560A (is)	2002-09-20	Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
HUP0103856A3 (en)	2003-11-28	Pharmaceutical composition for the treatment of acute disorders
IL143979A0 (en)	2002-04-21	Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
DE69925571D1 (de)	2005-07-07	Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems
NO20021845L (no)	2002-04-19	Behandling av sovnforstyrrelser under anvendelse av desloratadin
DK1165510T3 (da)	2006-02-06	1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser
AU6910600A (en)	2001-03-19	Methods for the treatment of mental disorders
DK1339406T3 (da)	2004-09-27	Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
IS4274A (is)	1995-10-12	Imidasópýridínsambönd til að nota við meðhöndlun sjúkdóma í meltingarvegi
IS6137A (is)	2001-10-30	Meðhöndlun á hugsýkistruflunum
ID27214A (id)	2001-03-08	Triazolopiridina untuk pengobatan gangguan trombosis
NO20012106L (no)	2001-06-21	Middel for behandling av forstyrrelser i benmetabolismen
ATE292107T1 (de)	2005-04-15	Verwendung von carbonylaminoderivaten gegen zentralnervensystem-störungen
PT1294710E (pt)	2005-10-31	Derivados de indole uteis para o tratamento de disturbios do snc
IS2172B (is)	2006-11-15	Indól afleiður sem eru nytsamlegar fyrir meðhöndlun á taugakerfistruflunum
IS6098A (is)	2001-09-28	Ósantant til meðhöndlunar á skaptruflunum
NO20034740L (no)	2003-10-23	Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser
DE60103761D1 (de)	2004-07-15	Indolderivate zum gebrauch in der behandlung von zns-störungen
NO20012538D0 (no)	2001-05-23	Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
ATE262525T1 (de)	2004-04-15	Indolderivate zur verwendung in der behandlung von zns-störungen
GB0010496D0 (en)	2000-06-14	Treatment of conditions of the central nervous system